JP6283861B2 - Ｕｂｅ２ｔペプチドおよびそれを含むワクチン - Google Patents

Ｕｂｅ２ｔペプチドおよびそれを含むワクチン Download PDF

Info

Publication number
JP6283861B2
JP6283861B2 JP2015530559A JP2015530559A JP6283861B2 JP 6283861 B2 JP6283861 B2 JP 6283861B2 JP 2015530559 A JP2015530559 A JP 2015530559A JP 2015530559 A JP2015530559 A JP 2015530559A JP 6283861 B2 JP6283861 B2 JP 6283861B2
Authority
JP
Japan
Prior art keywords
peptide
ube2t
seq
ctl
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015530559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529219A5 (enExample
JP2015529219A (ja
Inventor
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
朝久 渡辺
朝久 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2015529219A publication Critical patent/JP2015529219A/ja
Publication of JP2015529219A5 publication Critical patent/JP2015529219A5/ja
Application granted granted Critical
Publication of JP6283861B2 publication Critical patent/JP6283861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JP2015530559A 2012-09-11 2013-09-09 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン Active JP6283861B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699550P 2012-09-11 2012-09-11
US61/699,550 2012-09-11
PCT/JP2013/005321 WO2014041784A1 (en) 2012-09-11 2013-09-09 Ube2t peptides and vaccines containing the same

Publications (3)

Publication Number Publication Date
JP2015529219A JP2015529219A (ja) 2015-10-05
JP2015529219A5 JP2015529219A5 (enExample) 2016-10-13
JP6283861B2 true JP6283861B2 (ja) 2018-02-28

Family

ID=50277926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015530559A Active JP6283861B2 (ja) 2012-09-11 2013-09-09 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン

Country Status (17)

Country Link
US (2) US10092634B2 (enExample)
EP (1) EP2895600B1 (enExample)
JP (1) JP6283861B2 (enExample)
KR (1) KR102110873B1 (enExample)
CN (2) CN107881158B (enExample)
AU (1) AU2013317194B2 (enExample)
BR (1) BR112015004349B1 (enExample)
CA (1) CA2873155C (enExample)
DK (1) DK2895600T3 (enExample)
ES (1) ES2784862T3 (enExample)
IL (1) IL236690B (enExample)
MX (1) MX362912B (enExample)
PL (1) PL2895600T3 (enExample)
RU (1) RU2663350C2 (enExample)
SG (2) SG10201701866QA (enExample)
TW (1) TWI632162B (enExample)
WO (1) WO2014041784A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098387B2 (en) 2015-10-19 2024-09-24 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
JP6715004B2 (ja) 2015-12-25 2020-07-01 宏 半田 免疫賦活化剤およびその製造方法
CN110191703B (zh) 2017-01-25 2022-04-08 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
CN111787930B (zh) * 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113679829B (zh) 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
TR200100916T2 (enExample) 1998-07-14 2002-06-21 Corixa@@Corporation
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
AU2002227498A1 (en) * 2000-07-31 2002-02-13 Kyogo Itoh Tumor antigen
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
US20070202109A1 (en) 2003-09-24 2007-08-30 Oncotherapy Science, Inc. Method Of Diagnosing Breast Cancer
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
TWI494319B (zh) 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW200908998A (en) 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
EP2340851A4 (en) 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
KR20110117112A (ko) 2008-12-24 2011-10-26 온코세라피 사이언스 가부시키가이샤 Ｃ１ｏｒｆ５９ 펩티드 및 이를 포함하는 백신
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
TW201216982A (en) 2010-10-21 2012-05-01 Oncotherapy Science Inc WDHD1 peptides and vaccines including the same
US20130287805A1 (en) 2010-10-21 2013-10-31 Yusuke Nakamura C18orf54 peptides and vaccines including the same
TWI618541B (zh) 2010-12-02 2018-03-21 腫瘤療法 科學股份有限公司 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗

Also Published As

Publication number Publication date
CN104619833A (zh) 2015-05-13
EP2895600B1 (en) 2020-02-19
EP2895600A1 (en) 2015-07-22
TWI632162B (zh) 2018-08-11
TW201414752A (zh) 2014-04-16
CN107881158A (zh) 2018-04-06
WO2014041784A1 (en) 2014-03-20
MX2015003017A (es) 2015-06-10
CA2873155A1 (en) 2014-03-20
HK1212730A1 (en) 2016-06-17
MX362912B (es) 2019-02-22
BR112015004349A2 (pt) 2017-08-08
EP2895600A4 (en) 2016-05-04
CN104619833B (zh) 2018-01-02
BR112015004349B1 (pt) 2022-11-01
SG10201701866QA (en) 2017-04-27
JP2015529219A (ja) 2015-10-05
ES2784862T3 (es) 2020-10-01
IL236690A0 (en) 2015-02-26
KR20150054710A (ko) 2015-05-20
CA2873155C (en) 2022-07-26
RU2015113436A (ru) 2016-11-10
US20150174223A1 (en) 2015-06-25
AU2013317194A1 (en) 2015-02-05
CN107881158B (zh) 2021-11-16
PL2895600T3 (pl) 2020-10-05
AU2013317194B2 (en) 2018-07-12
KR102110873B1 (ko) 2020-05-14
IL236690B (en) 2021-03-25
US20180360938A1 (en) 2018-12-20
SG11201501761SA (en) 2015-04-29
RU2663350C2 (ru) 2018-08-03
US11266729B2 (en) 2022-03-08
US10092634B2 (en) 2018-10-09
DK2895600T3 (da) 2020-04-27

Similar Documents

Publication Publication Date Title
JP6295491B2 (ja) Ｋｎｔｃ２ペプチドおよびそれを含むワクチン
JP6349560B2 (ja) Ｔｏｐｋペプチドおよびそれを含むワクチン
US11266729B2 (en) UBE2T peptides and vaccines containing the same
JP5884104B2 (ja) 改変ｍｅｌｋペプチドおよびそれを含むワクチン
JP2013523084A (ja) Ｃｄｃａ５ペプチドおよびそれを含むワクチン
JP5564730B2 (ja) Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP2014519311A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2016222676A (ja) Ｔｏｍｍ３４ペプチドおよびそれを含むワクチン
JP5786178B2 (ja) Ｔｔｋペプチドおよびそれを含むワクチン
JP5838482B2 (ja) Ｈｊｕｒｐペプチドおよびそれを含むワクチン
US8697631B2 (en) TMEM22 peptides and vaccines including the same
JP2013540419A (ja) Ｔｔｌｌ４ペプチドおよびそれを含むワクチン
JP2016502499A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2014500001A (ja) Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン
JP2014504146A (ja) Ｗｄｈｄ１ペプチドおよびそれを含むワクチン
WO2014106886A1 (en) Cdca5 peptides and vaccines containing the same
HK1212730B (en) Ube2t peptides and vaccines containing the same
JP2013523083A (ja) Ｃｌｕａｐ１ペプチドおよびそれを含むワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180110

R150 Certificate of patent or registration of utility model

Ref document number: 6283861

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250